Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
A. García Herola, P. Nos Mateu, J. Ponce García.
Anticuerpos frente al citoplasma de los neutrófilos (ANCA) en la enfermedad inflamatoria crónica intestinal.
Gastroenterol Hepatol, 23 (2000), pp. 16-23
[2.]
F.J. Van der Woude, N. Rasmussen, S. Lobatto, A. Wiik, H. Permin, L.A. Van Es, et al.
Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis.
Lancet, 1 (1985), pp. 425-429
[3.]
N. Rasmussen, C. Sjolin, B. Isaksson, P. Bygren, J. Wieslander.
An ELISA for the detection of anti-neutrophil cytoplasm antibodies (ANCA).
J Immunol Methods, 127 (1990), pp. 139-145
[4.]
P.M. Ellerbroek, M. Oudkerk Pool, B.U. Ridwan, K.M. Dolman, B.M. Von Blomberg, A.E. Von dem Borne, et al.
Neutrophil cytoplasmic antibodies (p-ANCA) in ulcerative colitis.
J Clin Pathol, 47 (1994), pp. 257-262
[5.]
U. Muller-Ladner, V. Gross, T. Andus, H. Gschwendtner, M. Roth, I. Caesar, et al.
Distinct patterns of immunoglobulin classes and IgG subclasses of autoantibodies in patients with inflammatory bowel disease.
Eur J Gastroenterol Hepatol, 8 (1996), pp. 579-584
[6.]
M. Esteve, J. Mallolas, J. Klaassen, A. Abad-Lacruz, F. González-Huix, E. Cabre, et al.
Factors related to the presence of IgA class antineutrophil cytoplasmic antibodies in ulcerative colitis.
Am J Gastroenterol, 93 (1998), pp. 615-618
[7.]
R.M. Barnes, S. Allan, C.H. Taylor-Robinson, R. Finn, P.M. Johnson.
Serum antibodies reactive with Saccharomyces cerevisiae in inflammatory bowel disease: is IgA antibody a marker for Crohn's disease?.
Int Arch Allergy Appl Immunol, 92 (1990), pp. 9-15
[8.]
M.H. Giaffer, A. Clark, C.D. Holdsworth.
Antibodies to Saccharomyces cerevisiae in patients with Crohn's disease and their possible pathogenic importance.
Gut, 33 (1992), pp. 1071-1075
[9.]
E. Lindberg, K.E. Magnusson, C. Tysk, G. Jarnerot.
Antibody (IgG, IgA, and IgM) to baker's yeast (Saccharomyces cerevisiae), yeast mannan, gliadin, ovalbumin and betalactoglobulin in monozygotic twins with inflammatory bowel disease.
Gut, 33 (1992), pp. 909-913
[10.]
F.M. Ruemmele, S.R. Targan, G. Levy, M. Dubinsky, J. Braun, E.G. Seidman.
Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease.
Gastroenterology, 115 (1998), pp. 822-829
[11.]
C.L. Sutton, H. Yang, Z. Li, J.I. Rotter, S.R. Targan, J. Braun.
Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in affected and unaffected relatives of patients with Crohn's disease.
Gut, 46 (2000), pp. 58-63
[12.]
R. Panaccione, W.J. Sandborn.
Is antibody testing for inflammatory bowel disease clinically useful?.
Gastroenterology, 116 (1999), pp. 1001-1002
[13.]
S.R. Targan.
The utility of ANCA and ASCA in inflammatory bowel disease.
Inflamm Bowel Dis, 5 (1999), pp. 61-63
[14.]
Sandborn WJ, Loftus EV Jr, Colombel JF, Fleming KA, Seibold F, Homburger HA, et al. Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's disease. Inflamm Bowel Dis 2 0 0 1; 7 : 192-201
[15.]
K. Conrad, H. Schmechta, A. Klafki, G. Lobeck, H.H. Uhlig, S. Gerdi, et al.
Serological differentiation of inflammatory bowel diseases.
Eur J Gastroenterol Hepatol, 14 (2002), pp. 129-135
[16.]
P. Rutgeerts, S. Vermeire.
Clinical value of the detection of antibodies in the serum for diagnosis and treatment of inflammatory bowel disease.
Gastroenterology, 115 (1998), pp. 1006-1009
[17.]
R.P. MacDermott.
Lack of current clinical value of serological testing in the evaluation of patients with IBD.
Inflamm Bowel Dis, 5 (1999), pp. 64-65
[18.]
D.H. Present, P.A. Banks.
The role of pANCA and ASCA in differentiating ulcerative colitis, Crohn's disease, and indeterminate colitis.
Inflamm Bowel Dis, 5 (1999), pp. 66-67
[19.]
D.H. Present.
Serologic tests are not helpful in managing inflammatory bowel disease.
Inflamm Bowel Dis, 8 (2002), pp. 227-229
[20.]
J.A. Rump, J. Scholmerich, V. Gross, M. Roth, R. Helfesrieder, A. Rautmann, et al.
A new type of perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) in active ulcerative colitis but not in Crohn's disease.
Immunobiology, 181 (1990), pp. 406-413
[21.]
T. Schlenker, S. Apenberg, R. Raedsch, K. Andrassy, J. Plachky, B. Kommerell.
Antineutrophil cytoplasmic antibodies in chronic inflammatory bowel diseases.
Dtsch Med Wochenschr, 117 (1992), pp. 1463-1468
[22.]
F. Seibold, P. Weber, R. Klein, P.A. Berg, K.H. Wiedmann.
Clinical significance of antibodies against neutrophils in patients with inflammatory bowel disease and primary sclerosing cholangitis.
Gut, 33 (1992), pp. 657-662
[23.]
J.A. Rump, M. Roth, J. Scholmerich, R. Helfesrieder, J. Ludemann, W.L. Gross, et al.
A new type of ANCA in sera of patients with ulcerative colitis: effects of therapy and disease severity on serum titer.
Immun Infekt, 20 (1992), pp. 16-18
[24.]
R. Proujansky, P.T. Fawcett, K.M. Gibney, W.R. Treem, J.S. Hyams.
Examination of anti-neutrophil cytoplasmic antibodies in childhood inflammatory bowel disease.
J Pediatr Gastroenterol Nutr, 17 (1993), pp. 193-197
[25.]
G.N. Dalekos, M.N. Manoussakis, A.C. Goussia, E.V. Tsianos, H.M. Moutsopoulos.
Soluble interleukin-2 receptors, antineutrophil cytoplasmic antibodies, and other autoantibodies in patients with ulcerative colitis.
Gut, 34 (1993), pp. 658-664
[26.]
M. Oudkerk Pool, P.M. Ellerbroek, B.U. Ridwan, R. Goldschmeding, B.M. von Blomberg, A.S. Pena, et al.
Serum antineutrophil cytoplasmic autoantibodies in inflammatory b o w e l disease are mainly associated with ulcerative colitis. A correlation study between perinuclear antineutrophil cytoplasmic autoantibodies and clinical parameters, medical, and surgical treatment.
Gut, 34 (1993), pp. 46-50
[27.]
D. Reumaux, J.F. Colombel, B. Duclos, S. Chaussade, J. Belaiche, S. Jacquot, et al.
Antineutrophil cytoplasmic auto-antibodies in sera from patients with ulcerative colitis after proctocolectomy with ileo-anal anastomosis.
Adv Exp Med Biol, 336 (1993), pp. 523-525
[28.]
J.Y. Sung, F.K. Chan, J. Lawton, J.C. Leung, C.T. Liew, N.W. Leung, et al.
Anti-neutrophil cytoplasmic antibodies (ANCA) and inflammatory bowel diseases in Chinese.
Dig Dis Sci, 39 (1994), pp. 886-892
[29.]
J.A. Rump, I. Worner, M. Roth, J. Scholmerich, M. Hansch, H.H. Peter.
p-ANCA of undefined specificity in ulcerative colitis: correlation to disease activity and therapy.
Adv Exp Med Biol, 336 (1993), pp. 507-513
[30.]
A. Lamproye, J. Belaiche, E. Louis, J. Salmon, P. Mahieu.
Antineutrophil cytoplasmic antibodies (ANCA) in inflammatory diseases of the digestive tract.
Acta Gastroenterol Belg, 57 (1994), pp. 171-176
[31.]
A.H. Mulder, J. Broekroelofs, G. Horst, P.C. Limburg, G.F. Nelis, C.G. Kallenberg.
Anti-neutrophil cytoplasmic antibodies (ANCA) in inflammatory bowel disease: characterization and clinical correlates.
Clin Exp Immunol, 95 (1994), pp. 490-497
[32.]
J. Broekroelofs, A.H. Mulder, G.F. Nelis, B.D. Westerveld, J.W. Tervaert, C.G. Kallenberg.
Anti-neutrophil cytoplasmic antibodies (ANCA) in sera from patients with inflammatory bowel disease (IBD). Relation to disease pattern and disease activity.
Dig Dis Sci, 39 (1994), pp. 545-549
[33.]
M. Vecchi, M.B. Bianchi, R.A. Sinico, A. Radice, G. Meucci, G. Torgano, et al.
Antibodies to neutrophil cytoplasm in Italian patients with ulcerative colitis: sensitivity, specificity and recognition of putative antigens.
Digestion, 55 (1994), pp. 34-39
[34.]
J.C. Lee, J.E. Lennard-Jones, G. Cambridge.
Antineutrophil antibodies in familial inflammatory bowel disease.
Gastroenterology, 108 (1995), pp. 428-433
[35.]
W.H. Kim, P.M. Choi, C.J. Landers, S.R. Targan.
Role of antineutrophil cytoplasmic antibodies in an ethnically distinct population: Korean patients with ulcerative colitis.
Am J Gastroenterol, 90 (1995), pp. 1953-1958
[36.]
K. Kaneko, Y. Suzuki, T. Shimizu, Y. Yamashiro, K. Yabuta, C.H. Lifschitz.
Anti-neutrophil cytoplasmic antibodies in Japanese children with ulcerative colitis.
J Paediatr Child Health, 31 (1995), pp. 336-338
[37.]
D.S. Bansi, R.W. Chapman, K.A. Fleming.
Prevalence and diagnostic role of antineutrophil cytoplasmic antibodies in inflammatory bowel disease.
Eur J Gastroenterol Hepatol, 8 (1996), pp. 881-885
[38.]
M. Papo, J.C. Quer, R.M. Pastor, G. García-Pardo, E. Prats, E. Mirapeix, et al.
Antineutrophil cytoplasmic antibodies in relatives of patients with inflammatory bowel disease.
Am J Gastroenterol, 91 (1996), pp. 1512-1515
[39.]
M. Esteve, J. Mallolas, J. Klaassen, A. Abad-Lacruz, F. González-Huix, E. Cabre, et al.
Antineutrophil cytoplasmic antibodies in sera from colectomised ulcerative colitis patients and its relation to the presence of pouchitis.
Gut, 38 (1996), pp. 894-898
[40.]
H. Freeman, B. Roeck, D. Devine, C. Carter.
Prospective evaluation of neutrophil autoantibodies in 500 consecutive patients with inflammatory bowel disease.
Can J Gastroenterol, 11 (1997), pp. 203-207
[41.]
P. Gigase, L.S. De Clerck, K.A. Van Cotthem, C.H. Bridts, W.J. Stevens, M. Van Outryve, et al.
Anti-neutrophil cytoplasmic antibodies in inflammatory bowel disease with special attention for IgA-class antibodies.
Dig Dis Sci, 42 (1997), pp. 2171-2174
[42.]
J.P. Olives, A. Breton, J.P. Hugot, F. Oksman, C. Johannet, J. Ghisolfi, et al.
Antineutrophil cytoplasmic antibodies in children with inflammatory bowel disease: prevalence and diagnostic value.
J Pediatr Gastroenterol Nutr, 25 (1997), pp. 142-148
[43.]
E. Abad, C. Tural, E. Mirapeix, A. Cuxart.
Relationship between ANCA and clinical activity in inflammatory bowel disease: variation in prevalence of ANCA and evidence of heterogeneity.
J Autoimmun, 10 (1997), pp. 175-180
[44.]
A. García-Herola, P. Nos, M. Hoyos, J. Hinojosa, J.R. Moles, S. Pascual, et al.
Significado de la determinación de anticuerpos frente al citoplasma de los neutrófilos (ANCA) en la colitis ulcerosa y en la enfermedad de Crohn.
Gastroenterol Hepatol, 21 (1998), pp. 169-173
[45.]
J.F. Quinton, B. Sendid, D. Reumaux, P. Duthilleul, A. Cortot, B. Grandbastien, et al.
Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role.
Gut, 42 (1998), pp. 788-791
[46.]
K. Kull, R. Salupere, R. Uibo, M. Ots, V. Salupere.
Antineutrophil cytoplasmic antibodies in Estonian patients with inflammatory bowel disease. Prevalence and diagnostic role.
Hepatogastroenterology, 45 (1998), pp. 2132-2137
[47.]
A. Sediva, I. Kolarova, J. Bartunkova.
Antineutrophil cytoplasmic antibodies in children.
Eur J Pediatr, 157 (1998), pp. 987-991
[48.]
C. Folwaczny, M. Jochum, N. Noehl, D. Schnettler, K. Loeschke, H. Fricke.
p-ANCA target antigens in ulcerative colitis.
Z Gastroenterol, 36 (1998), pp. 625-633
[49.]
J. Satsangi, C.J. Landers, K.I. Welsh, K. Koss, S. Targan, D.P. Jewell.
The presence of anti-neutrophil antibodies reflects clinical and genetic heterogeneity within inflammatory bowel disease.
Inflamm Bowel Dis, 4 (1998), pp. 18-26
[50.]
M. Papo, J.C. Quer, R.M. Pastor, G. Garcia-Pardo, M. Olona, E. Prats, et al.
Anticuerpos anticitoplasma de neutrófilo en la enfermedad inflamatoria del intestino.
Med Clin (Barc), 110 (1998), pp. 11-15
[51.]
M. Vecchi, M.B. Bianchi, C. Calabresi, G. Meucci, M. Tatarella, R. De Franchis.
Long-term observation of the perinuclear antineutrophil cytoplasmic antibody status in ulcerative colitis patients.
Scand J Gastroenterol, 33 (1998), pp. 170-173
[52.]
E.J. Hoffenberg, S. Fidanza, A. Sauaia.
Serologic testing for inflammatory bowel disease.
J Pediatr, 134 (1999), pp. 447-452
[53.]
C. Roozendaal, K. Pogany, G. Horst, T.G. Jagt, J.H. Kleibeuker, G.F. Nelis, et al.
Does analysis of the antigenic specificities of anti-neutrophil cytoplasmic antibodies contribute to their clinical significance in the inflammatory bowel diseases?.
Scand J Gastroenterol, 34 (1999), pp. 1123-1131
[54.]
C. Taddei, M.A. Audrain, D. Reumaux, R. Sesboue, A. Testa, J.P. Galmiche, et al.
Alpha1-antitrypsin phenotypes and antineutrophil cytoplasmic auto-antibodies in inflammatory bowel disease.
Eur J Gastroenterol Hepatol, 11 (1999), pp. 1293-1298
[55.]
K. Sugi, O. Saitoh, R. Matsuse, K. Tabata, K. Uchida, K. Kojima, et al.
Antineutrophil cytoplasmic antibodies in Japanese patients with inflammatory bowel disease: prevalence and recognition of putative antigens.
Am J Gastroenterol, 94 (1999), pp. 1304-1312
[56.]
D. Reumaux, J.F. Colombel, E. Masy, B. Duclos, D. Heresbach, J. Belaiche, et al.
Anti-neutrophil cytoplasmic auto-antibodies (ANCA) in ulcerative colitis (UC): no relationship with disease activity.
Inflamm Bowel Dis, 6 (2000), pp. 270-274
[57.]
G. Lombardi, V. Annese, A. Piepoli, P. Bovio, A. Latiano, G. Napolitano, et al.
Antineutrophil cytoplasmic antibodies in inflammatory bowel disease: clinical role and review of the literature.
Dis Colon Rectum, 43 (2000), pp. 999-1007
[58.]
M. Peeters, S. Joossens, S. Vermeire, R. Vlietinck, X. Bossuyt, P. Rutgeerts.
Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease.
Am J Gastroenterol, 96 (2001), pp. 730-734
[59.]
K. Malickova, I. Janatkova, T. Fucikova, S. Adamec, M. Lukas.
Initial experience with detection of Saccharomyces cerevisiae antibodies in patients with primary nonspecific inflammatory bowel disease.
Epidemiol Mikrobiol Imunol, 50 (2001), pp. 131-135
[60.]
I.E. Koutroubakis, E. Petinaki, I.A. Mouzas, I.G. Vlachonikolis, E. Anagnostopoulou, E. Castanas, et al.
Anti-Saccharomyces cerevisiae mannan antibodies and antineutrophil cytoplasmic autoantibodies in Greek patients with inflammatory bowel disease.
Am J Gastroenterol, 96 (2001), pp. 449-454
[61.]
S. Vermeire, M. Peeters, R. Vlietinck, S. Joossens, E. Den Hond, V. Bulteel, et al.
Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD and intestinal permeability: a study in IBD families.
Inflamm Bowel Dis, 7 (2001), pp. 8-15
[62.]
P.R. Fleshner, E.A. Vasiliauskas, L.Y. Kam, N.E. Fleshner, J. Gaiennie, M.T. Abreu-Martin, et al.
High level perinuclear antineutrophil cytoplasmic antibody (pANCA) in ulcerative colitis patients before colectomy predicts the development of chronic pouchitis after ileal pouch-anal anastomosis.
Gut, 49 (2001), pp. 671-677
[63.]
C. Osangthamnont, S. Manatsathit, S. Pongprasopchai, R. Viriyataveekul, S. Chaihirunkarn, S. Leelakusolvong, et al.
Antibodies to neutrophil cytoplasma in patients with ulcerative colitis and their first-degree relatives in Thailand.
J Gastroenterol Hepatol, 16 (2001), pp. 866-871
[64.]
P. Lecis, B. Germana, N. Papa, G. Bertiato, C. Doglioni, E. Galliani, et al.
In process citation.
Recenti Prog Med, 93 (2002), pp. 308-313
[65.]
J. Bartunkova, I. Kolarova, A. Sediva, E. Holzelova.
Antineutrophil cytoplasmic antibodies, anti-Saccharomyces cerevisiae antibodies, and specific IgE to food allergens in children with inflammatory bowel diseases.
Clin Immunol, 102 (2002), pp. 162-168
[66.]
J. Ehrmann, M. Konecny, J. Bartek, Z. Hermanova, I. Krc.
c-ANCA and p-ANCA in patients with Crohn's disease.
Acta Univ Palacki Olomuc Fac Med, 140 (1996), pp. 49-51
[67.]
E.A. Vasiliauskas, L.Y. Kam, L.C. Karp, J. Gaiennie, H. Yang, S.R. Targan.
Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics.
Gut, 47 (2000), pp. 487-496
[68.]
B. Sendid, J.F. Quinton, G. Charrier, O. Goulet, A. Cortot, B. Grandbastien, et al.
Anti-Saccharomyces cerevisiae mannan antibodies in familial Crohn's disease.
Am J Gastroenterol, 93 (1998), pp. 1306-1310
[69.]
C.J. Darroch, R.M. Barnes, J. Dawson.
Circulating antibodies to Saccharomyces cerevisiae (bakers'/brewers' yeast) in gastrointestinal disease.
J Clin Pathol, 52 (1999), pp. 47-53
[70.]
V. Annese, A. Andreoli, A. Andriulli, R. Dinca, P. Gionchetti, A. Latiano, et al.
Familial expression of anti-Saccharomyces cerevisiae Mannan antibodies in Crohn's disease and ulcerative colitis: a GISC study.
Am J Gastroenterol, 96 (2001), pp. 2407-2412
[71.]
S. Vermeire, S. Joossens, M. Peeters, F. Monsuur, G. Marien, X. Bossuyt, et al.
Comparative study of ASCA (anti-Saccharomyces cerevisiae antibody) assays in inflammatory bowel disease.
Gastroenterology, 120 (2001), pp. 827-833
[72.]
F. Seibold, O. Stich, R. Hufnagl, S. Kamil, M. Scheurlen.
Anti-Saccharomyces cerevisiae antibodies in inflammatory bowel disease: a family study.
Scand J Gastroenterol, 36 (2001), pp. 196-201
[73.]
C.N. Bernstein, K. Orr, J.F. Blanchard, M. Sargent, D. Workman.
Development of an assay for antibodies to Saccharomyces cerevisiae: easy, cheap and specific for Crohn's disease.
Can J Gastroenterol, 15 (2001), pp. 499-504
[74.]
X. Liu, T. Yu, M. Zhao.
The diagnostic significance of antineutrophil cytoplasmic antibodies in ulcerative colitis.
Zhonghua Nei Ke Za Zhi, 38 (1999), pp. 451-454
[75.]
M. Oudkerk Pool, G. Bouma, S.G. Meuwissen, B.M. von Blomberg, J.P. van de Merwe, W.L. Deville, et al.
Serological markers to differentiate between ulcerative colitis and Crohn's disease.
J Clin Pathol, 48 (1995), pp. 346-350
[76.]
B. Sendid, J.F. Colombel, P.M. Jacquinot, C. Faille, J. Fruit, A. Cortot, et al.
Specific antibody response to oligomannosidic epitopes in Crohn's disease.
Clin Diagn Lab Immunol, 3 (1996), pp. 219-226
[77.]
F. Seibold, D. Slametschka, M. Gregor, P. Weber.
Neutrophil autoantibodies: a genetic marker in primary sclerosing cholangitis and ulcerative colitis.
Gastroenterology, 107 (1994), pp. 532-536
[78.]
H.S. Winter, C.J. Landers, A. Winkelstein, A. Vidrich, S.R. Targan.
Anti-neutrophil cytoplasmic antibodies in children with ulcerative colitis.
J Pediatr, 125 (1994), pp. 707-711
[79.]
F. Castellino, F. Rosina, D.S. Bansi, M. Bauducci, G.A. Touscoz, L. Giorda, et al.
Anti-neutrophil cytoplasmic antibodies in inflammatory bowel disease: do they recognize different subsets of a heterogeneous disease?.
Eur J Gastroenterol Hepatol, 7 (1995), pp. 859-864
[80.]
A. Lerner, Y. Shoenfeld.
Serological markers in inflammatory bowel disease: the pros and cons.
Eur J Gastroenterol Hepatol, 14 (2002), pp. 103-105
[81.]
M.M. Moore, D. Fabricatorian, W.S. Selby.
Assessment and relevance of enzyme-linked immunosorbent assay for antibodies to Saccharomyces cerevisiae in Australian patients with inflammatory bowel disease.
Intern Med J, 32 (2002), pp. 349-352
[82.]
M.T. Abreu.
Controversies in IBD. Serologic tests are helpful in managing inflammatory bowel disease.
Inflamm Bowel Dis, 8 (2002), pp. 224-226
[83.]
T.J. Fagan.
Nomogram for Bayes theorem [letter].
N Engl J Med, 293 (1975), pp. 257
[84.]
J. Stewenius, I. Adnerhill, G. Ekelund, C.H. Floren, F.T. Fork, L. Janzon, et al.
Ulcerative colitis and indeterminate colitis in the city of Malmo, Sweden. A 25-year incidence study.
Scand J Gastroenterol, 30 (1995), pp. 38-43
[85.]
K.A. Papadakis, S.R. Targan.
Serologic testing in inflammatory bowel disease: its value in indeterminate colitis.
Curr Gastroenterol Rep, 1 (1999), pp. 482-485
[86.]
S. Joossens, W. Reinisch, S. Vermeire, B. Sendid, D. Poulain, M. Peeters, et al.
The value of serologic markers in indeterminate colitis: a prospective follow-up study.
Gastroenterology, 122 (2002), pp. 1242-1247
[87.]
A. Saxon, F. Shanahan, C. Landers, T. Ganz, S. Targan.
A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease.
J Allergy Clin Immunol, 86 (1990), pp. 202-210
[88.]
D.S. Bansi, S. Lo, R.W. Chapman, K.A. Fleming.
Absence of antineutrophil cytoplasmic antibodies in relatives of UK patients with primary sclerosing cholangitis and ulcerative colitis.
Eur J Gastroenterol Hepatol, 8 (1996), pp. 111-116
[89.]
M.L. Andreani, G. Frasca, G. Brusco, L. Borgnino, F. Biagi, G. Gasbarrini, et al.
Antineutrophil cytoplasmic antibodies in inflammatory bowel disease: diagnostic tool or research procedure?.
Ann Ital Med Int, 11 (1996), pp. 254-257
[90.]
G. Cambridge, D.S. Rampton, T.R. Stevens, D.A. McCarthy, M. Kamm, B. Leaker.
Anti-neutrophil antibodies in inflammatory bowel disease: prevalence and diagnostic role.
Gut, 33 (1992), pp. 668-674
[91.]
R.T. Patel, R. Stokes, D. Birch, J. Ibbotson, M.R. Keighley.
Influence of total colectomy on serum antineutrophil cytoplasmic antibodies in inflammatory bowel disease.
Br J Surg, 81 (1994), pp. 724-726
[92.]
W.J. Sandborn, C.J. Landers, W.J. Tremaine, S.R. Targan.
Antineutrophil cytoplasmic antibody correlates with chronic pouchitis after ileal pouch-anal anastomosis.
Am J Gastroenterol, 90 (1995), pp. 740-747
[93.]
W.J. Sandborn, C.J. Landers, W.J. Tremaine, S.R. Targan.
Association of antineutrophil cytoplasmic antibodies with resistance to treatment of left-sided ulcerative colitis: results of a pilot study.
Mayo Clin Proc, 71 (1996), pp. 431-436
[94.]
E.A. Vasiliauskas, S.E. Plevy, C.J. Landers, S.W. Binder, D.M. Ferguson, H. Yang, et al.
Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup.
Gastroenterology, 110 (1996), pp. 1810-1819
[95.]
M. Vecchi, P. Gionchetti, M.B. Bianchi, A. Belluzzi, G. Meucci, M. Campieri, et al.
p-ANCA and development of pouchitis in ulcerative colitis patients after proctocolectomy and ileoanal pouch anastomosis.
Lancet, 344 (1994), pp. 886-887
[96.]
S. Lindgren, C.H. Floren, T. Lindhagen, M. Starck, J. Stewenius, L. Nassberger.
Low prevalence of anti-neutrophil cytoplasmic antibodies in ulcerative colitis patients with long-term remission.
Eur J Gastroenterol Hepatol, 7 (1995), pp. 563-568
[97.]
E. Hertervig, J. Wieslander, C. Johansson, A. Wiik, A. Nilsson.
Anti-neutrophil cytoplasmic antibodies in chronic inflammatory bowel disease. Prevalence and diagnostic role.
Scand J Gastroenterol, 30 (1995), pp. 693-698
[98.]
N. Jamar-Leclerc, D. Reumaux, P. Duthilleul, J.F. Colombel.
Do pANCA define a clinical subgroup in patients with Crohn's disease?.
Gastroenterology, 112 (1997), pp. 316-317
[99.]
J. Main, H. McKenzie, G.R. Yeaman, M.A. Kerr, D. Robson, C.R. Pennington, et al.
Antibody to Saccharomyces cerevisiae (bakers' yeast) in Crohn's disease.
BMJ, 297 (1988), pp. 1105-1106
[100.]
N. Oshitani, F. Hato, T. Matsumoto, Y. Jinno, Y. Sawa, J. Hara, et al.
Decreased anti-Saccharomyces cerevisiae antibody titer by mesalazine in patients with Crohn's disease.
J Gastroenterol Hepatol, 15 (2000), pp. 1400-1403
[101.]
R. Sostegni, M. Daperno, E. Ercole, C. Rigazio, F. Bresso, G. Masoero, et al.
Detection of anti-Saccharomyces cerevisiae antibodies in Crohn's disease: is it a reliable diagnostic and prognostic marker?.
Dig Liver Dis, 33 (2001), pp. 755-761
[102.]
R.H. Duerr, S.R. Targan, C.J. Landers, L.R. Sutherland, F. Shanahan.
Anti-neutrophil cytoplasmic antibodies in ulcerative colitis. Comparison with other colitides/diarrheal illnesses.
Gastroenterology, 100 (1991), pp. 1590-1596
[103.]
D.S. Bansi, K.A. Fleming, R.W. Chapman.
Importance of antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis and ulcerative colitis: prevalence, titre, and IgG subclass.
Gut, 38 (1996), pp. 384-389
[104.]
A. Frenzer, W. Fierz, E. Rundler, B. Hammer, J. Binek.
Atypical, cytoplasmic and perinuclear anti-neutrophil cytoplasmic antibodies in patients with inflammatory bowel disease.
J Gastroenterol Hepatol, 13 (1998), pp. 950-954
[105.]
C. Roozendaal, K. Pogany, E.J. Hummel, G. Horst, G. Dijkstra, G.F. Nelis, et al.
Titres of anti-neutrophil cytoplasmic antibodies in inflammatory bowel disease are not related to disease activity.
QJM, 92 (1999), pp. 651-658
[106.]
J.F. Colombel, D. Reumaux, P. Duthilleul, L.H. Noel, C. Gower-Rousseau, J.C. Paris, et al.
Antineutrophil cytoplasmic autoantibodies in inflammatory bowel diseases.
Gastroenterol Clin Biol, 16 (1992), pp. 656-660
[107.]
D. Reumaux, J.F. Colombel, L. Delecourt, L.H. Noel, A. Cortot, P. Duthilleul.
Anti-neutrophil cytoplasmic auto-antibodies (ANCA) in patients with ulcerative colitis (UC): influence of disease activity and familial study.
Adv Exp Med Biol, 336 (1993), pp. 515-518
[108.]
C.A. Young, A. Sonnenberg, E.A. Burns.
Lymphocyte proliferation response to baker's yeast in Crohn's disease.
Digestion, 55 (1994), pp. 40-43
[109.]
F. Shanahan, R.H. Duerr, J.I. Rotter, H. Yang, L.R. Sutherland, C. McElree, et al.
Neutrophil autoantibodies in ulcerative colitis: familial aggregation and genetic heterogeneity.
Gastroenterology, 103 (1992), pp. 456-461
[110.]
C. Folwaczny, N. Noehl, S.P. Endres, W. Heldwein, K. Loeschke, H. Fricke.
Antinuclear autoantibodies in patients with inflammatory bowel disease. High prevalence in first-degree relatives.
Dig Dis Sci, 42 (1997), pp. 1593-1597
[111.]
P. Yang, G. Jarnerot, D. Danielsson, C. Tysk, E. Lindberg.
p-ANCA in monozygotic twins with inflammatory bowel disease.
Gut, 36 (1995), pp. 887-890
[112.]
K.D. Taylor, S.E. Plevy, H. Yang, C.J. Landers, M.J. Barry, J.I. Rotter, et al.
ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease.
Gastroenterology, 120 (2001), pp. 1347-1355
[113.]
P. Aitola, A. Miettinen, A. Mattila, M. Matikainen, E. Soppi.
Effect of proctocolectomy on serum antineutrophil cytoplasmic antibodies in patients with chronic ulcerative colitis.
J Clin Pathol, 48 (1995), pp. 645-647
[114.]
P. Yang, T. Oresland, G. Jarnerot, L. Hulten, D. Danielsson.
Perinuclear antineutrophil cytoplasmic antibody in pouchitis after proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis.
Scand J Gastroenterol, 31 (1996), pp. 594-598
[115.]
J. Aisenberg, J. Wagreich, J. Shim, S. Almer, E. Peen, T. Heimann, et al.
Perinuclear anti-neutrophil cytoplasmic antibody and refractory pouchitis. A case-control study.
Dig Dis Sci, 40 (1995), pp. 1866-1872
[116.]
H.J. Freeman, B. Roeck, D.V. Devine, C.J. Carter.
Atypical perinuclear antineutrophil cytoplasmic antibodies after colectomy in inflammatory bowel disease.
Can J Gastroenterol, 11 (1997), pp. 305-310
[117.]
A.G. Kaditis, J. Perrault, W.J. Sandborn, C.J. Landers, A.R. Zinsmeister, S.R. Targan.
Antineutrophil cytoplasmic antibody subtypes in children and adolescents after ileal pouchanal anastomosis for ulcerative colitis.
J Pediatr Gastroenterol Nutr, 26 (1998), pp. 386-392
[118.]
O.H. Nielsen, B. Vainer, S.M. Madsen, J.B. Seidelin, N.H. Heegaard.
Established and emerging biological activity markers of inflammatory bowel disease.
Am J Gastroenterol, 95 (2000), pp. 359-367
Copyright © 2003. Elsevier España, S.L.. Todos los derechos reservados
